UCB Pharma SA: Clinical Trials

17 trials sponsored by UCB Pharma SA, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

17 completed. 17 Phase 3.

By phase and status

Phase	Trials	Status
Phase 3	17	Completed 17

Follow UCB Pharma SA: new trials by email

Trials (filtered) newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044 Certolizumab Pegol - Rheumatoid Arthritis	Phase 3	Completed	UCB Pharma SA	347	2014-11-01	2018-10-16
Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures Levetiracetam, Carbamazepine - Epilepsy, Partial Seizures	Phase 3	Completed	UCB Pharma SA	436	2013-09-01	2017-08-15
Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures Lacosamide - Epilepsy, Partial-onset Seizures	Phase 3	Completed	UCB Pharma SA	473	2013-03-26	2021-08-17
Scintigraphic Detection of the Biodistribution of Tumor Necrosis Factor With a Radiolabeled Anti-TNFα in Patients With Active Rheumatoid Arthritis and Active Axial and Peripheral Spondyloarthritis administration of Cimzia®, Immunoscintigraphy with radiolabeled Cimzia®. - Axial and Peripheral Spondyloarthritis, Rheumatoid Arthritis	Phase 3	Completed	University Hospital, Ghent	41	2012-10-18	2019-08-26
Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy Brivaracetam - Epilepsy	Phase 3	Completed	UCB Pharma SA	26	2012-10-01	2018-07-11
A Trial to Evaluate the Efficacy and Safety of Adjunctive Therapy With Lacosamide in Adults With Partial-Onset Seizures Lacosamide 50 mg, Lacosamide 100 mg, Placebo - Epilepsy, Partial Onset Seizures	Phase 3	Completed	UCB Pharma SA	548	2012-09-01	2017-08-25
Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV) Brivaracetam - Epilepsy	Phase 3	Completed	UCB Pharma SA	29	2012-07-01	2018-07-11
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis Certolizumab Pegol, Placebo, Methotrexate - Rheumatoid Arthritis	Phase 3	Completed	UCB Pharma SA	880	2012-01-01	2026-08-25
Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy Brivaracetam (BRV) - Epilepsy	Phase 3	Completed	UCB Pharma SA	257	2011-08-01	2025-10-20
Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From Epilepsy Placebo, Brivaracetam - Epilepsy	Phase 3	Completed	UCB Pharma SA	480	2007-10-01	2018-04-03
Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures Placebo, Brivaracetam - Epilepsy	Phase 3	Completed	UCB Pharma SA	399	2007-09-01	2022-07-21
Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and Adults Brivaracetam 25 mg, Brivaracetam 50 mg, Placebo - Unverricht-Lundborg Disease	Phase 3	Completed	UCB Pharma SA	50	2006-11-01	2015-05-18
Monotherapy With Levetiracetam in Patients Suffering From Epilepsy. Levetiracetam - Epilepsy, Tonic-clonic	Phase 3	Completed	UCB Pharma SA	66	2005-08-10	2018-11-21
A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Certolizumab Pegol (CDP870) - Crohn's Disease	Phase 3	Completed	UCB Pharma SA	596	2004-07-01	2018-08-01
A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease Certolizumab Pegol (CDP870) - Crohn's Disease	Phase 3	Completed	UCB Pharma SA	310	2004-02-01	2018-08-07
Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM) Placebo, Levocetirizine - Dermatitis, Atopic	Phase 3	Completed	UCB Pharma SA	514	2002-03-20	2019-01-22
Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and Older With Generalized Epilepsy Levetiracetam 166 mg, Levetiracetam 250 mg, Levetiracetam 500 mg - Generalized Epilepsy	Phase 3	Completed	UCB Pharma SA	217	2001-11-01	2020-07-29

Conditions studied

Interventions

Countries

Top investigators

Results publications

NIH funding